Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation

BackgroundHemostasis is a critical and active function of the blood mediated by platelets. Therefore, the prevention of pathological platelet aggregation is of great importance as well as of pharmaceutical and medical interest. Endogenous platelet inhibition is predominantly based on cyclic nucleotides (cAMP, cGMP) elevation and subsequent cyclic nucleotide-dependent protein kinase (PKA, PKG) activation. In turn, platelet phosphodiesterases (PDEs) and protein phosphatases counterbalance their activity. This main inhibitory pathway in human platelets is crucial for countervailing unwanted platelet activation. Consequently, the regulators of cyclic nucleotide signaling are of particular interest to pharmacology and therapeutics of atherothrombosis. Modeling of pharmacodynamics allows understanding this intricate signaling and supports the precise description of these pivotal targets for pharmacological modulation.ResultsWe modeled dynamically concentration-dependent responses of pathway effectors (inhibitors, activators, drug combinations) to cyclic nucleotide signaling as well as to downstream signaling events and verified resulting model predictions by experimental data. Experiments with various cAMP affecting compounds including anti-platelet drugs and their combinations revealed a high fidelity, fine-tuned cAMP signaling in platelets without cross-talk to the cGMP pathway. The model and the data provide evidence for two independent feedback loops: PKA, which is activated by elevated cAMP levels in the platelet, subsequently inhibits adenylyl cyclase (AC) but as well activates PDE3. By multi-experiment fitting, we established a comprehensive dynamic model with one predictive, optimized and validated set of parameters. Different pharmacological conditions (inhibition, activation, drug combinations, permanent and transient perturbations) are successfully tested and simulated, including statistical validation and sensitivity analysis. Downstream cyclic nucleotide signaling events target different phosphorylation sites for cAMP- and cGMP-dependent protein kinases (PKA, PKG) in the vasodilator-stimulated phosphoprotein (VASP). VASP phosphorylation as well as cAMP levels resulting from different drug strengths and combined stimulants were quantitatively modeled. These predictions were again experimentally validated. High sensitivity of the signaling pathway at low concentrations is involved in a fine-tuned balance as well as stable activation of this inhibitory cyclic nucleotide pathway.ConclusionsOn the basis of experimental data, literature mining and database screening we established a dynamic in silico model of cyclic nucleotide signaling and probed its signaling sensitivity. Thoroughly validated, it successfully predicts drug combination effects on platelet function, including synergism, antagonism and regulatory loops.

[1]  M. Krieger,et al.  cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. , 1994, The Journal of biological chemistry.

[2]  R. Haslam,et al.  Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. , 1994, European journal of pharmacology.

[3]  Regina Z. Cer,et al.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..

[4]  U. Walter,et al.  Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. , 1998, European journal of pharmacology.

[5]  S. Døskeland,et al.  Cyclic nucleotide analogs as probes of signaling pathways , 2008, Nature Methods.

[6]  R. Schreiber,et al.  Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance , 2004, Neuropharmacology.

[7]  N. Suttorp,et al.  Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. , 2005, Blood.

[8]  Ursula Klingmüller,et al.  Theoretical and experimental analysis links isoform- specific ERK signalling to cell fate decisions , 2009, Molecular systems biology.

[9]  A. Michelson.  Antiplatelet therapies for the treatment of cardiovascular disease , 2010, Nature Reviews Drug Discovery.

[10]  J. Corbin,et al.  Activation of the particulate low Km phosphodiesterase of adipocytes by addition of cAMP-dependent protein kinase. , 1988, The Journal of biological chemistry.

[11]  J. Beavo,et al.  Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. , 1988, The Journal of biological chemistry.

[12]  T. Dandekar,et al.  Platelet Protein Interactions: Map, Signaling Components, and Phosphorylation Groundstate , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[13]  M. Kikura,et al.  Pharmacokinetics of Intravenous Milrinone in Patients Undergoing Cardiac Surgery , 1994, Anesthesiology.

[14]  J. Kawabe,et al.  Regulation of Adenylyl Cyclase by Protein Kinase A (*) , 1995, The Journal of Biological Chemistry.

[15]  Thomas F. Coleman,et al.  An Interior Trust Region Approach for Nonlinear Minimization Subject to Bounds , 1993, SIAM J. Optim..

[16]  U. Walter,et al.  Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors. , 1994, Biochemical pharmacology.

[17]  M. Kendall.  Theoretical Statistics , 1956, Nature.

[18]  J. Muehlschlegel,et al.  Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. , 2006, British journal of anaesthesia.

[19]  J. Timmer,et al.  Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Iyengar,et al.  Adenylyl cyclase 6 is selectively regulated by protein kinase A phosphorylation in a region involved in Galphas stimulation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  U. Walter,et al.  Analysis and Regulation of Vasodilator-stimulated Phosphoprotein Serine 239 Phosphorylation in Vitro and in Intact Cells Using a Phosphospecific Monoclonal Antibody* , 1998, The Journal of Biological Chemistry.

[22]  Natal A. W. van Riel,et al.  Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments , 2006, Briefings Bioinform..

[23]  Hisham S. Elbatarny,et al.  Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions , 2008, Proceedings of the National Academy of Sciences.

[24]  J. Corbin,et al.  cAMP-dependent protein kinase activation lowers hepatocyte cAMP. , 1985, The Journal of biological chemistry.

[25]  C. Lamberg-Allardt,et al.  Rapid Protein Kinase A—Mediated Activation of Cyclic AMP‐Phosphodiesterase by Parathyroid Hormone in UMR‐106 Osteoblast‐like Cells , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  D. Campbell,et al.  Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. , 2005, The Biochemical journal.

[27]  B. Mayer,et al.  Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. , 2001, Molecular pharmacology.

[28]  T. MacDonald,et al.  Antiplatelet drug interactions , 2010, Journal of internal medicine.

[29]  Hong Zhao,et al.  Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty. , 2007, American journal of physiology. Heart and circulatory physiology.

[30]  Jens Timmer,et al.  Dynamical modeling and multi-experiment fitting with PottersWheel , 2008, Bioinform..

[31]  I. Hers,et al.  Protein Kinase C-mediated Phosphorylation and Activation of PDE3A Regulate cAMP Levels in Human Platelets* , 2009, Journal of Biological Chemistry.

[32]  M. Conti,et al.  Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. , 1995, Molecular pharmacology.

[33]  J. Beavo,et al.  Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases* , 1998, The Journal of Biological Chemistry.

[34]  M. Lohse,et al.  Real-time monitoring of phosphodiesterase inhibition in intact cells. , 2008, Cellular signalling.

[35]  E. Rimm,et al.  Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition , 2008, Circulation research.

[36]  M. Gomberg-Maitland,et al.  Prostacyclin therapies for the treatment of pulmonary arterial hypertension , 2008, European Respiratory Journal.

[37]  C. Van Geet,et al.  Regulators of platelet cAMP levels: clinical and therapeutic implications. , 2010, Current medicinal chemistry.

[38]  Manuela Zaccolo,et al.  of in The Role of the in the A Molecular for Generating cAMP and cGMP Signaling Cross-Talk Role of Phosphodiesterases and Implications for Cardiac Pathophysiology , 2007 .

[39]  R. Sprague,et al.  Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP. , 2008, American journal of physiology. Heart and circulatory physiology.

[40]  R. Colman,et al.  Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. , 2002, Molecular pharmacology.

[41]  T. Dandekar,et al.  Analysis of SAGE data in human platelets: Features of the transcriptome in an anucleate cell , 2006, Thrombosis and Haemostasis.

[42]  Bo Zhang,et al.  A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.

[43]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[44]  T. Podzuweit,et al.  Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. , 1995, Cellular signalling.

[45]  E. Porreca,et al.  Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study , 2008, Pharmacogenetics and genomics.

[46]  Zhiliang Xu,et al.  A multiscale model of thrombus development , 2008, Journal of The Royal Society Interface.

[47]  V. Ferrans,et al.  Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3) , 2000, The Journal of Biological Chemistry.

[48]  U. Walter,et al.  Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. , 1992, European journal of biochemistry.

[49]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[50]  Y. Rao,et al.  Assessment of myocardial blood perfusion improved by CD151 in a pig myocardial infarction model , 2009, Acta Pharmacologica Sinica.

[51]  D. Tilley,et al.  Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. , 2002, Diabetes.

[52]  J. Geiger.  Inhibitors of platelet signal transduction as anti-aggregatory drugs , 2001, Expert opinion on investigational drugs.

[53]  B. Sanwal,et al.  Regulatory mechanisms involved in the control of cyclic adenosine 3':5'-monophosphate phosphodiesterases in myoblasts. , 1980, The Journal of biological chemistry.

[54]  C. Daub,et al.  BMC Systems Biology , 2007 .

[55]  M. Houslay.  Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[56]  G. Makhlouf,et al.  PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. , 2002, American journal of physiology. Cell physiology.

[57]  K. Kamata,et al.  Phosphodiesterases in the vascular system. , 2003, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[58]  T. Dandekar,et al.  Characterization of a Novel Interaction Between Vasodilator-Stimulated Phosphoprotein and Abelson Interactor 1 in Human Platelets: A Concerted Computational and Experimental Approach , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[59]  S. Kuo,et al.  YC‐1 inhibited human platelet aggregation through NO‐independent activation of soluble guanylate cyclase , 1995, British journal of pharmacology.

[60]  U. Walter,et al.  Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human Platelets: In Vitro and In Vivo/Ex Vivo Studies , 2003, Stroke.

[61]  U. Walter,et al.  Inhibition of platelet P2Y12 and alpha2A receptor signaling by cGMP-dependent protein kinase. , 2002, Biochemical pharmacology.

[62]  U. Walter,et al.  Taming platelets with cyclic nucleotides. , 2001, Biochemical pharmacology.

[63]  B. Tabakoff,et al.  Platelet Adenylyl Cyclase Activity: A Biological Marker for Major Depression and Recent Drug Use , 2005, Biological Psychiatry.

[64]  J. Kotera,et al.  Overview of PDEs and Their Regulation , 2007, Circulation research.

[65]  T. Eschenhagen,et al.  Capturing adenylyl cyclases as potential drug targets , 2009, Nature Reviews Drug Discovery.

[66]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[67]  Oliver Sawodny,et al.  Mechanism of PP2A-mediated IKKβ dephosphorylation: a systems biological approach , 2009, BMC Systems Biology.

[68]  J. Heemskerk,et al.  Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. , 2004, Biochemical pharmacology.

[69]  Ming-yu Hsieh,et al.  Spatio-temporal modeling of signaling protein recruitment to EGFR , 2010, BMC Systems Biology.

[70]  J. Geiger,et al.  A protein phosphorylation-based assay for screening and monitoring of drugs modulating cyclic nucleotide pathways. , 2010, Analytical biochemistry.

[71]  C. Robert Cloninger,et al.  Platelet adenylyl cyclase activity in alcoholics and subtypes of alcoholics. WHO/ISBRA Study Clinical Centers. , 1996, Alcoholism, clinical and experimental research.

[72]  Avner Friedman,et al.  A continuum mathematical model of endothelial layer maintenance and senescence , 2007, Theoretical Biology and Medical Modelling.

[73]  P. Fossa,et al.  New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[74]  A. Hoffmann,et al.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. , 2002, Science.

[75]  G. Baillie.  Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases , 2009, The FEBS journal.

[76]  R. Fischmeister,et al.  cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. , 1997, The Journal of clinical investigation.